DNA Methylation-Mediated Overexpression of CXCL1 in Helicobacter pylori-Induced Gastric Cancer: In Silico- and In Vitro-Based Identification of a Potential Biomarker for Carcinogenesis

Muhammad, Jibran Sualeh; Manzoor, Shaista; Cui, Zheng‐Guo; Khoder, Ghalia

doi:10.3390/ijms24010795

Cited by 6 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We begin with gastric cancer, given the vast literature on H. pylori as the canonical bacterial carcinogen [60]. Mechanistically, H. pylori-related changes in the tumor microenvironment contribute to tumor progression and immune tolerance by causing chronic inflammation [61], genetic alteration including DNA methylation and chromosmomal instability [62][63][64], and immune suppression [65]. H. pylori-induced inflammation can create conditions ripe for EMT, by upregulating the expression of pro-angiogenic factors such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and matrix metalloproteinases (MMPs) [66][67][68].…”

Section: Mechanisms Of Microbiome Impact On Esophageal and Gastric Ca...mentioning

confidence: 99%

The Influence of the Microbiome on Immunotherapy for Gastroesophageal Cancer

Dadgar,

Edlukudige Keshava,

Raj

et al. 2023

Cancers

View full text Add to dashboard Cite

Immunotherapy has shown promise as a treatment option for gastroesophageal cancer, but its effectiveness is limited in many patients due to the immunosuppressive tumor microenvironment (TME) commonly found in gastrointestinal tumors. This paper explores the impact of the microbiome on the TME and immunotherapy outcomes in gastroesophageal cancer. The microbiome, comprising microorganisms within the gastrointestinal tract, as well as within malignant tissue, plays a crucial role in modulating immune responses and tumor development. Dysbiosis and reduced microbial diversity are associated with poor response rates and treatment resistance, while specific microbial profiles correlate with improved outcomes. Understanding the complex interactions between the microbiome, tumor biology, and immunotherapy is crucial for developing targeted interventions. Microbiome-based biomarkers may enable personalized treatment approaches and prediction of patient response. Interventions targeting the microbiome, such as microbiota-based therapeutics and dietary modifications, offer the potential for reshaping the gut microbiota and creating a favorable TME that enhances immunotherapy efficacy. Further research is needed to reveal the underlying mechanisms, and large-scale clinical trials will be required to validate the efficacy of microbiome-targeted interventions.

show abstract

Section: Mechanisms Of Microbiome Impact On Esophageal and Gastric Ca...mentioning

confidence: 99%

The Influence of the Microbiome on Immunotherapy for Gastroesophageal Cancer

Dadgar,

Edlukudige Keshava,

Raj

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

Epigenetic regulation in cancer

Gu,

Ren,

Fang

et al. 2024

MedComm

View full text Add to dashboard Cite

Epigenetic modifications are defined as heritable changes in gene activity that do not involve changes in the underlying DNA sequence. The oncogenic process is driven by the accumulation of alterations that impact genome's structure and function. Genetic mutations, which directly disrupt the DNA sequence, are complemented by epigenetic modifications that modulate gene expression, thereby facilitating the acquisition of malignant characteristics. Principals among these epigenetic changes are shifts in DNA methylation and histone mark patterns, which promote tumor development and metastasis. Notably, the reversible nature of epigenetic alterations, as opposed to the permanence of genetic changes, positions the epigenetic machinery as a prime target in the discovery of novel therapeutics. Our review delves into the complexities of epigenetic regulation, exploring its profound effects on tumor initiation, metastatic behavior, metabolic pathways, and the tumor microenvironment. We place a particular emphasis on the dysregulation at each level of epigenetic modulation, including but not limited to, the aberrations in enzymes responsible for DNA methylation and histone modification, subunit loss or fusions in chromatin remodeling complexes, and the disturbances in higher‐order chromatin structure. Finally, we also evaluate therapeutic approaches that leverage the growing understanding of chromatin dysregulation, offering new avenues for cancer treatment.

show abstract